Cooper Companies, Inc. (COO) was founded in 1958 and has operated as a publicly traded company on the S&P 500 index since 2016. Headquartered in Pleasanton, California, the firm employs over 15,000 people worldwide and serves more than 50 million end users across its two primary business segments. The presentation at the 44th Annual J.P. Morgan Healthcare Conference highlighted the company’s 68-year track record of profitability and its disciplined approach to capital allocation, including a consistent dividend policy and opportunistic share repurchases.

CooperCompanies operates under two distinct units: CooperVision and CooperSurgical. CooperVision—responsible for roughly two-thirds of consolidated revenues—is one of the world’s largest contact lens manufacturers, supplying over 42 million wearers annually. CooperSurgical focuses on women’s health and fertility, delivering non-pharmaceutical medical devices and diagnostic products. During the presentation, management emphasized the segment’s double-digit growth in in vitro fertilization consumables and expanding adoption of genetic carrier screening solutions.

Within the global contact lens market, CooperVision holds the number one position by wearer count and ranks second by revenue. The company cited strong market share in silicone hydrogel and daily disposable lenses, backed by recent approvals of toric and multifocal designs. In the fertility space, CooperSurgical boasts leadership in embryo transfer catheters and surgical tools, with a presence in over 100 countries and coverage of more than 1 million IVF cycles per year. Management noted a combined market share exceeding 25% in their key product categories.

Looking ahead, CooperCompanies plans to accelerate growth through new product launches, geographic expansion in emerging markets, and targeted acquisitions. Key initiatives include the rollout of an advanced high-oxygen-permeability contact lens in Asia Pacific and expansion of CooperSurgical’s genetic testing portfolio in North America and Europe. Management reaffirmed its mid-single-digit revenue growth target for fiscal 2026 and anticipates adjusted EBITDA margins in the range of 27% to 29%, driven by operational efficiencies and pricing discipline.